Parkinson’s Disease: Linking mitochondria to the immune response
A gene associated with Parkinson’s disease regulates mitochondrial homeostasis, thus affecting innate immunity.
- Department for Neuroscience, University of Florida College of Medicine, United States
- Center for Translational Research in Neurodegenerative Disease, University of Florida College of Medicine, United States
Parkinson’s disease is a motor disorder caused by the loss of a specific sub-set of neurons located in the midbrain and the accumulation of a protein called α-synuclein. The underlying mechanisms that lead to the death of the midbrain neurons are still not well understood. However, many individuals with Parkinson’s disease have increased levels of inflammation in the brain and in peripheral organs, such as the gut. This inflammation is now viewed as a potential contributor to Parkinson’s disease, and not just a result of it.
Mutations in the gene coding for the kinase LRRK2 are the most common genetic cause of inherited Parkinson’s disease (Singleton et al., 2013). Single nucleotide polymorphisms in this gene are also associated with increased susceptibility to inflammatory diseases such as leprosy – which, like tuberculosis, is caused by a mycobacterium – and irritable bowel disease (Fava et al., 2016; Witoelar et al., 2017; Villumsen et al., 2019). Mounting evidence suggests that mutations in LRRK2 contribute to immune alterations in both peripheral organs and the brain (Wallings and Tansey, 2019), but the mechanisms through which LRRK2 regulates these immune responses are poorly understood.
Aside from its link to inflammation, LRRK2 has also been implicated in the activity of mitochondria, which are key subcellular organelles linked to Parkinson’s disease (Singh et al., 2019; Park et al., 2018). For example, neural stem cells derived from the skin of individuals carrying a mutation associated with Parkinson’s disease in the gene for LRRK2 exhibit increased mitochondrial DNA damage as well as increased oxidative damage (Howlett et al., 2017; Sanders et al., 2014). Despite this, the contribution of LRRK2 to mitochondrial health in cells of the peripheral immune system has been understudied. Now, in eLife, Robert Watson and colleagues from Texas A&M University – including Chi Weindel and Samantha Bell as joint first authors – report that LRRK2’s ability to influence inflammatory responses in peripheral immune cells is directly linked to its role in maintaining mitochondrial homeostasis (Weindel et al., 2020).
To investigate the role of LRRK2 in peripheral immune responses, Weindel et al. isolated macrophages from the bone marrow of mice lacking the gene that codes for the mouse homolog of LRRK2 (Lrrk2 knockout macrophages). Compared to macrophages with a single copy of this gene (Lrrk2 HETs), the knockout macrophages upregulated genes normally stimulated by interferons (signaling proteins that recruit immune cells to trigger an immune response). Weindel et al. also found that these macrophages were unable to upregulate interferon response genes when they were infected with mycobacteria, likely because these genes were already chronically activated.
Moreover, when mice lacking Lrrk2 were infected with Mycobacterium tuberculosis, which causes tuberculosis, their lungs exhibited exacerbated local inflammation caused by the infection. However, no differences in the outcome of the infection were observed in these mice relative to the Lrrk2 HETs. This contradicts previous reports suggesting that mice lacking Lrrk2 can stop M. tuberculosis replication more effectively than wild-type mice, correlating with increased inflammation in the lungs (Härtlova et al., 2018). One possible reason for this inconsistency is that Weindel et al. used Lrrk2 heterozygous controls as opposed to wild-type controls. Furthermore, different M. tuberculosis strains were used in the two studies, and there were also differences in the number of bacteria that mice were exposed to during infection.
Since LRRK2 is also involved in mitochondrial activity, Weindel et al. next looked at the mitochondria in Lrrk2 knockout macrophages. Mitochondria are dynamic organelles that can divide (fragment) or fuse depending on the state of the cell. When a cell is stressed, mitochondria fuse together to exchange damaged DNA and keep aerobic respiration going. Weindel et al. observed that in macrophages lacking Lrrk2, mitochondria did not fuse, making the macrophages more susceptible to stress, and leading to mitochondrial DNA leaking into the cytosol. This was due, in part, to increased activation of DRP1, a protein that helps mitochondria fragment. Inhibiting DRP1 successfully rescued these abnormal mitochondria in Lrrk2 knockout macrophages. Weindel et al. also reported reduced antioxidant levels, a concomitant accumulation of reactive oxygen species, and increased mitochondrial stress in macrophages lacking Lrrk2. Treating these macrophages with antioxidants alleviated mitochondrial stress (Figure 1).
Figure 1
Interactions between mitochondrial homeostasis and immune response in a Lrrk2 knockout macrophage.
(Top) Loss of Lrrk2 in mouse macrophages increases DRP1 phosphorylation. This leads to an increase in the level of mitochondrial DNA (mtDNA; red bean-shaped structures) in the cytosol, which activates the cGAS/STING pathway. This, in turn, triggers the phosphorylation of transcription factors that activate the expression of interferon (IFN) response genes in the nucleus, which leads to a lowered response to interferon from these cells. In this situation, antioxidant levels in the cell are low and mitochondrial stress increases. (Bottom) Three different treatments can partially or totally rescue inflammatory deficits in Lrrk2 knockout macrophages. First, treating these macrophages with antioxidants alleviates mitochondrial stress and rescues the normal response to interferon. Second, inhibiting DRP1 phosphorylation decreases fission, lowering the level of mitochondrial DNA (green bean-shaped structures) in the cytosol. This prevents the activation of the cGAS/STING pathway, and consequently, the abnormal activation of interferon response genes. Third (and confirming this finding), removing the cGas gene also mitigates increased interferon stimulated gene expression.
The increased mitochondrial DNA in the cytosol of Lrrk2 knockout macrophages led Weindel et al. to hypothesize that the inability to regulate mitochondrial homeostasis could be contributing to chronic activation of interferon response genes. The cGAS–STING pathway is a part of the innate immune system that triggers the expression of inflammatory genes when DNA is detected in the cytosol. Weindel et al. showed that loss of the cGas gene decreased basal levels of type I interferon in Lrrk2 knockout macrophages and corrected the response to immune stimuli (Figure 1).
These findings link the role of LRRK2 in innate immune dysregulation with its critical function in maintaining mitochondrial homeostasis for the first time and have wider implications for the field of Parkinson’s disease. Future research will likely investigate how mutations in the gene for LRRK2 affect the relationship between mitochondria and inflammation in immune cells. The most common of these mutations causes a toxic increase in kinase activity, so kinase inhibitors have been considered for their potential therapeutic effects in Parkinson’s disease. However, given that loss of LRRK2 may lead to higher risks of infection and inflammation in peripheral blood cells, therapeutic windows will have to be carefully monitored to avoid unwanted effects on the immune system.
References
-
A missense LRRK2 variant is a risk factor for excessive inflammatory responses in leprosyPLOS Neglected Tropical Diseases 10:e0004412.https://doi.org/10.1371/journal.pntd.0004412
-
Mitochondrial dysfunction in Parkinson's disease: new mechanistic insights and therapeutic perspectivesCurrent Neurology and Neuroscience Reports 18:21.https://doi.org/10.1007/s11910-018-0829-3
-
LRRK2 and mitochondria: recent advances and current viewsBrain Research 1702:96–104.https://doi.org/10.1016/j.brainres.2018.06.010
-
The genetics of Parkinson's disease: progress and therapeutic implicationsMovement Disorders 28:14–23.https://doi.org/10.1002/mds.25249
-
LRRK2 regulation of immune-pathways and inflammatory diseaseBiochemical Society Transactions 47:1581–1595.https://doi.org/10.1042/BST20180463
Article and author information
Author details
Rebecca L Wallings
Publication history
- Version of Record published: April 15, 2020 (version 1)
Copyright
© 2020, Wallings et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,683
- views
-
- 342
- downloads
-
- 7
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Parkinson’s Disease: Linking mitochondria to the immune response
eLife 9:e56214.
https://doi.org/10.7554/eLife.56214
Further reading
-
- Immunology and Inflammation
We studied lysosomal Ca2+ in inflammasome. Lipopolysaccharide (LPS) + palmitic acid (PA) decreased lysosomal Ca2+ ([Ca2+]Lys) and increased [Ca2+]i through mitochondrial ROS, which was suppressed in Trpm2-KO macrophages. Inflammasome activation and metabolic inflammation in adipose tissue of high-fat diet (HFD)-fed mice were ameliorated by Trpm2 KO. ER→lysosome Ca2+ refilling occurred after lysosomal Ca2+ release whose blockade attenuated LPS + PA-induced inflammasome. Subsequently, store-operated Ca2+entry (SOCE) was activated whose inhibition suppressed inflammasome. SOCE was coupled with K+ efflux whose inhibition reduced ER Ca2+ content ([Ca2+]ER) and impaired [Ca2+]Lys recovery. LPS + PA activated KCa3.1 channel, a Ca2+-activated K+ channel. Inhibitors of KCa3.1 channel or Kcnn4 KO reduced [Ca2+]ER, attenuated increase of [Ca2+]i or inflammasome activation by LPS + PA, and ameliorated HFD-induced inflammasome or metabolic inflammation. Lysosomal Ca2+ release induced delayed JNK and ASC phosphorylation through CAMKII-ASK1. These results suggest a novel role of lysosomal Ca2+ release sustained by ER→lysosome Ca2+ refilling and K+ efflux through KCa3.1 channel in inflammasome activation and metabolic inflammation.
-
- Immunology and Inflammation
The autoimmune disease lupus erythematosus (lupus) is characterized by photosensitivity, where even ambient ultraviolet radiation (UVR) exposure can lead to development of inflammatory skin lesions. We have previously shown that Langerhans cells (LCs) limit keratinocyte apoptosis and photosensitivity via a disintegrin and metalloprotease 17 (ADAM17)-mediated release of epidermal growth factor receptor (EGFR) ligands and that LC ADAM17 sheddase activity is reduced in lupus. Here, we sought to understand how the lupus skin environment contributes to LC ADAM17 dysfunction and, in the process, differentiate between effects on LC ADAM17 sheddase function, LC ADAM17 expression, and LC numbers. We show through transcriptomic analysis a shared IFN-rich environment in non-lesional skin across human lupus and three murine models: MRL/lpr, B6.Sle1yaa, and imiquimod (IMQ) mice. IFN-I inhibits LC ADAM17 sheddase activity in murine and human LCs, and IFNAR blockade in lupus model mice restores LC ADAM17 sheddase activity, all without consistent effects on LC ADAM17 protein expression or LC numbers. Anti-IFNAR-mediated LC ADAM17 sheddase function restoration is associated with reduced photosensitive responses that are dependent on EGFR signaling and LC ADAM17. Reactive oxygen species (ROS) is a known mediator of ADAM17 activity; we show that UVR-induced LC ROS production is reduced in lupus model mice, restored by anti-IFNAR, and is cytoplasmic in origin. Our findings suggest that IFN-I promotes photosensitivity at least in part by inhibiting UVR-induced LC ADAM17 sheddase function and raise the possibility that anifrolumab ameliorates lupus skin disease in part by restoring this function. This work provides insight into IFN-I-mediated disease mechanisms, LC regulation, and a potential mechanism of action for anifrolumab in lupus.
